CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents

AT Anshabo, R Milne, S Wang, H Albrecht - Frontiers in oncology, 2021 - frontiersin.org
Cyclin-dependent kinases (CDKs) are proteins pivotal to a wide range of cellular functions,
most importantly cell division and transcription, and their dysregulations have been …

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

Y Wang, J Chen, Z Wu, W Ding, S Gao… - British journal of …, 2021 - Wiley Online Library
Prostate cancer is the second most common malignancy in men and androgen deprivation
therapy is the first‐line therapy. However, most cases will eventually develop castration …

Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer

A Ghoochani, EC Hsu, M Aslan, MA Rice, HM Nguyen… - Cancer research, 2021 - AACR
Ferroptosis is a type of programmed cell death induced by the accumulation of lipid
peroxidation and lipid reactive oxygen species in cells. It has been recently demonstrated …

MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

X Qiu, N Boufaied, T Hallal, A Feit, A de Polo… - Nature …, 2022 - nature.com
Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …

Androgen receptor and MYC equilibration centralizes on developmental super-enhancer

H Guo, Y Wu, M Nouri, S Spisak, JW Russo… - Nature …, 2021 - nature.com
Androgen receptor (AR) in prostate cancer (PCa) can drive transcriptional repression of
multiple genes including MYC, and supraphysiological androgen is effective in some …

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair

AA Shafi, CM McNair, JJ McCann, M Alshalalfa… - Nature …, 2021 - nature.com
Mechanisms regulating DNA repair processes remain incompletely defined. Here, the
circadian factor CRY1, an evolutionally conserved transcriptional coregulator, is identified as …

International union of basic and clinical pharmacology CXIII: Nuclear receptor superfamily—Update 2023

TP Burris, IMS de Vera, I Cote, CA Flaveny… - Pharmacological …, 2023 - ASPET
The NR superfamily comprises 48 transcription factors in humans that control a plethora of
gene network programs involved in a wide range of physiologic processes. This review will …

A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression

AG Holmes, JB Parker, V Sagar, MI Truica, PN Soni… - Science …, 2022 - science.org
MYC regulates multiple gene programs, raising questions about the potential selectivity and
downstream transcriptional consequences of MYC inhibitors as cancer therapeutics. Here …

Discovery of small-molecule degraders of the CDK9-cyclin T1 complex for targeting transcriptional addiction in prostate cancer

J Li, T Liu, Y Song, M Wang, L Liu, H Zhu… - Journal of Medicinal …, 2022 - ACS Publications
Aberrant hyperactivation of cyclins results in carcinogenesis and therapy resistance in
cancers. Direct degradation of the specific cyclin or cyclin-dependent kinase (CDK)-cyclin …

KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis

T Limberger, M Schlederer, K Trachtová… - Molecular Cancer, 2022 - Springer
Background Frequent truncation mutations of the histone lysine N-methyltransferase KMT2C
have been detected by whole exome sequencing studies in various cancers, including …